- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.11. | Versant unveils Pep2Tango, a next-gen peptide biotech hoping to redefine obesity treatment | ||
| 21.11. | Enveda raises $130M series C to take more AI-discovered compounds into the clinic | ||
| 21.11. | BD teams up with MD Anderson, Su Clinica to study HPV self-collection tests in underserved Texas communities | ||
| 21.11. | Kyowa Kirin fronts $330M to share rights to Kura's leukemia drug ahead of push to FDA | ||
| 21.11. | Novartis, assessing peers' muscular dystrophy failures, pens $1.1B deal for gene therapy biotech | ||
| 21.11. | Novartis 'took data to heart' before slimming clinical pipeline by 40%, says CEO | ||
| 20.11. | Amgen taps Stanford's Howard Chang to take CSO reins from Jay Bradner | ||
| 20.11. | Viking pads case for MASH drug with final ph. 2 data showing significant reductions in liver fibrosis | ||
| 20.11. | Plant compound genipin restores nerves, physical sensation in mice with familial dysautonomia | ||
| 20.11. | Novartis taps Vyriad's viral vectors to develop in vivo T cell editing | ||
| 20.11. | Medtronic scores FDA clearance for smart insulin pen app aimed at multiple daily injections | ||
| 20.11. | Pfizer plucks internal candidate to replace R&D head Dolsten, triggering series of leadership shakeups | ||
| 20.11. | NewAmsterdam's cholesterol drug scores another phase 3 win-and disappoints investors again | ||
| 20.11. | Biotechs go big for bitcoin: Trio of companies each plan to stash $1M as reserve | ||
| 20.11. | Sage drops dalzanemdor as Huntington's failure completes clean sweep of midphase flops | ||
| 20.11. | Pfizer, Flagship return to obesity as part of latest additions to multibillion-dollar collaboration | ||
| 20.11. | Amid broader uncertainty, biopharma market may have reached 'new norm': PitchBook | ||
| 19.11. | CRO Lindus Health launches latest 'all-in-one' service for infectious disease clinical trials | ||
| 19.11. | Medtronic sees pulsed field ablation cut into cryo sales, amid supply issues | ||
| 19.11. | Jupiter takes off with $70M fund for cancer biotechs | ||
| 19.11. | AHA 2024: Boston Scientific, Abbott tout long-term heart occluder data | ||
| 19.11. | J&J, Protagonist's oral psoriasis prospect scores in phase 3 pair, readying case against BMS' Sotyktu | ||
| 19.11. | 'Some call it the J.P. Morgan of Europe': Jefferies' London conference goes big for 2024 | ||
| 19.11. | Canadian CRO Innovaderm looks to expand in Europe with new vice president | ||
| 19.11. | Lilly's lipoprotein-blocking heart med posts midstage win, turning up heat on potential AstraZeneca showdown |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
